The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD.
Hiroyuki KamaoErika MitsuiYuto DateKatsutoshi GotoKenichi MizukawaAtsushi MikiPublished in: Journal of ophthalmology (2024)
Switching to brolucizumab from aflibercept for eyes with nAMD with resistance to bimonthly injections of aflibercept is a valuable treatment option with and without the loading regimen. This trial is registered with UMIN000023676.